Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium tuberculosis | 3-oxoacyl-[acyl-carrier-protein] synthase III FabH (beta-ketoacyl-ACP synthase III) (KAS III) | 0.0667 | 1 | 1 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0026 | 0.012 | 0.012 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.0667 | 1 | 1 |
Mycobacterium ulcerans | long-chain-fatty-acid-CoA ligase | 0.0025 | 0.0096 | 0.0096 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0087 | 0.1053 | 1 |
Echinococcus multilocularis | tumor protein p63 | 0.035 | 0.5108 | 0.5 |
Brugia malayi | hypothetical protein | 0.0026 | 0.012 | 0.0065 |
Echinococcus granulosus | tumor protein p63 | 0.035 | 0.5108 | 0.5 |
Loa Loa (eye worm) | glutaminase | 0.0265 | 0.3795 | 1 |
Mycobacterium leprae | PROBABLE FATTY-ACID-CoA LIGASE FADD7 (FATTY-ACID-CoA SYNTHETASE) (FATTY-ACID-CoA SYNTHASE) | 0.0025 | 0.0096 | 0.5 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0087 | 0.1053 | 1 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.0026 | 0.012 | 0.5 |
Mycobacterium ulcerans | acyl-CoA synthetase | 0.0025 | 0.0096 | 0.0096 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0026 | 0.012 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0025 | 0.0096 | 0.0252 |
Mycobacterium ulcerans | acyl-CoA synthetase | 0.0025 | 0.0096 | 0.0096 |
Schistosoma mansoni | glutaminase | 0.0265 | 0.3795 | 1 |
Loa Loa (eye worm) | glutaminase 2 | 0.0265 | 0.3795 | 1 |
Plasmodium falciparum | beta-ketoacyl-ACP synthase III | 0.0667 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0026 | 0.012 | 0.0315 |
Brugia malayi | glutaminase DH11.1 | 0.0265 | 0.3795 | 1 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.0026 | 0.012 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0051 | 0.0506 | 0.1334 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0026 | 0.012 | 0.5 |
Trichomonas vaginalis | glutaminase, putative | 0.0265 | 0.3795 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0026 | 0.012 | 1 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.0026 | 0.012 | 0.012 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0087 | 0.1053 | 1 |
Mycobacterium ulcerans | glutaminase | 0.0265 | 0.3795 | 0.3795 |
Plasmodium vivax | beta-ketoacyl-acyl carrier protein synthase III precursor, putative | 0.0667 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | 3-oxoacyl-ACP synthase | 0.0667 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0025 | 0.0096 | 0.0252 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0026 | 0.012 | 0.012 |
Mycobacterium ulcerans | hypothetical protein | 0.0025 | 0.0096 | 0.0096 |
Mycobacterium ulcerans | fatty-acid-CoA ligase | 0.0025 | 0.0096 | 0.0096 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0087 | 0.1053 | 1 |
Mycobacterium tuberculosis | Probable fatty-acid-CoA ligase FadD2 (fatty-acid-CoA synthetase) (fatty-acid-CoA synthase) | 0.0025 | 0.0096 | 0.0096 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.0667 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0025 | 0.0096 | 0.0252 |
Mycobacterium leprae | PROBABLE FATTY-ACID-CoA LIGASE FADD2 (FATTY-ACID-CoA SYNTHETASE) (FATTY-ACID-CoA SYNTHASE) | 0.0025 | 0.0096 | 0.5 |
Mycobacterium ulcerans | acyl-CoA synthetase | 0.0025 | 0.0096 | 0.0096 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0087 | 0.1053 | 1 |
Mycobacterium ulcerans | long-chain fatty-acid CoA ligase | 0.0025 | 0.0096 | 0.0096 |
Mycobacterium tuberculosis | Probable chain -fatty-acid-CoA ligase FadD13 (fatty-acyl-CoA synthetase) | 0.0025 | 0.0096 | 0.0096 |
Mycobacterium ulcerans | beta-ketoacyl synthase-like protein | 0.0667 | 1 | 1 |
Onchocerca volvulus | 0.0051 | 0.0506 | 1 | |
Mycobacterium ulcerans | long-chain-fatty-acid--CoA ligase | 0.0025 | 0.0096 | 0.0096 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.